Characteristic analysis of adverse reactions of histone deacetylase inhibitors based on WHO-VigiAccess
BackgroundThis study assessed the adverse drug reactions (ADRs) associated with HDAC inhibitors using the VigiAccess database maintained by the World Health Organization (WHO). Furthermore, it compared the ADR profiles of three different drugs to identify the one with the lowest individualized risk...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-03-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1563797/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849774113791410176 |
|---|---|
| author | Tongnan Yin Yuyu Liu Chenwen Li Xinran Feng Yumeng Lin Zhongyu Qu |
| author_facet | Tongnan Yin Yuyu Liu Chenwen Li Xinran Feng Yumeng Lin Zhongyu Qu |
| author_sort | Tongnan Yin |
| collection | DOAJ |
| description | BackgroundThis study assessed the adverse drug reactions (ADRs) associated with HDAC inhibitors using the VigiAccess database maintained by the World Health Organization (WHO). Furthermore, it compared the ADR profiles of three different drugs to identify the one with the lowest individualized risk for patients.Materials and methodsData on adverse events of HDAC Inhibitors was retrieved from WHO-VigiAccess on 6 January 2025. We obtained data on age, gender, reporting year, and continent. Descriptive data related were calculated using Excel 2021. In this study, we used Excel software to analyze the characteristics of those who were harmed due to adverse reactions. For each drug, the reporting rate of adverse reactions was calculated by dividing the number of adverse reaction symptoms of this drug by the total number of adverse reaction reports. We listed the top 20 most frequent adverse reaction symptoms as common adverse reactions. By counting the frequency and proportion of these common adverse reactions, we conducted a comparative analysis of the adverse reaction situations of different drugs and classified them according to different types.ResultThe WHO-VigiAccess database received 796, 1254, and 1658 ADR reports for Chidamide, Romidepsin, and Vorinostat respectively by 2024, with a total of 3,708. Gender distribution was relatively balanced (male:female ratio 0.81:1), and the 45–64 age group had the highest reporting rates, mostly from the Americas. Chidamide had higher rates in certain disorders, Romidepsin in others, and Vorinostat in specific ones. Common ADRs included thrombocytopenia etc., with some differences in rates among drugs. Serious ADR proportions were 0% for Chidamide, 2.27% for Romidepsin, and 1.02% for Vorinostat. 37 common signals were found, with Investigations having the most. Each drug had different ADR preferred terms (PTs) in renal/urinary and metabolism/nutrition disorders, with varying numbers of distinctive symptoms.ConclusionCurrent comparative observational studies of these inhibitors indicate that there are both common and specific adverse reactions reported in the ADR data received by the WHO for these medications. Clinicians should enhance the rational use of these drugs by considering the characteristics of the reported ADRs. |
| format | Article |
| id | doaj-art-06df7fe5829d4b2dbb98d8496c79b871 |
| institution | DOAJ |
| issn | 1663-9812 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj-art-06df7fe5829d4b2dbb98d8496c79b8712025-08-20T03:01:50ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122025-03-011610.3389/fphar.2025.15637971563797Characteristic analysis of adverse reactions of histone deacetylase inhibitors based on WHO-VigiAccessTongnan Yin0Yuyu Liu1Chenwen Li2Xinran Feng3Yumeng Lin4Zhongyu Qu5Central Laboratory, Nanyang Central Hospital, Nanyang, ChinaSchool of Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, ChinaDepartment of Dermatology, Henan Provincial People’s Hospital, Henan University People’s Hospital, Zhengzhou, ChinaDepartment of Preventive Dentistry, School of Stomatology, The Fourth Military Medical University, Xi’an, ChinaHealth Management Center, Nanjing Tongren Hospital, School of Medicine, Southeast University, Nanjing, ChinaDepartment of Oncology, Nanyang Central Hospital, Nanyang, ChinaBackgroundThis study assessed the adverse drug reactions (ADRs) associated with HDAC inhibitors using the VigiAccess database maintained by the World Health Organization (WHO). Furthermore, it compared the ADR profiles of three different drugs to identify the one with the lowest individualized risk for patients.Materials and methodsData on adverse events of HDAC Inhibitors was retrieved from WHO-VigiAccess on 6 January 2025. We obtained data on age, gender, reporting year, and continent. Descriptive data related were calculated using Excel 2021. In this study, we used Excel software to analyze the characteristics of those who were harmed due to adverse reactions. For each drug, the reporting rate of adverse reactions was calculated by dividing the number of adverse reaction symptoms of this drug by the total number of adverse reaction reports. We listed the top 20 most frequent adverse reaction symptoms as common adverse reactions. By counting the frequency and proportion of these common adverse reactions, we conducted a comparative analysis of the adverse reaction situations of different drugs and classified them according to different types.ResultThe WHO-VigiAccess database received 796, 1254, and 1658 ADR reports for Chidamide, Romidepsin, and Vorinostat respectively by 2024, with a total of 3,708. Gender distribution was relatively balanced (male:female ratio 0.81:1), and the 45–64 age group had the highest reporting rates, mostly from the Americas. Chidamide had higher rates in certain disorders, Romidepsin in others, and Vorinostat in specific ones. Common ADRs included thrombocytopenia etc., with some differences in rates among drugs. Serious ADR proportions were 0% for Chidamide, 2.27% for Romidepsin, and 1.02% for Vorinostat. 37 common signals were found, with Investigations having the most. Each drug had different ADR preferred terms (PTs) in renal/urinary and metabolism/nutrition disorders, with varying numbers of distinctive symptoms.ConclusionCurrent comparative observational studies of these inhibitors indicate that there are both common and specific adverse reactions reported in the ADR data received by the WHO for these medications. Clinicians should enhance the rational use of these drugs by considering the characteristics of the reported ADRs.https://www.frontiersin.org/articles/10.3389/fphar.2025.1563797/fullhistone deacetylase inhibitoradverse drug reactionschidamideromidepsinvorinostatWHO-VigiAccess |
| spellingShingle | Tongnan Yin Yuyu Liu Chenwen Li Xinran Feng Yumeng Lin Zhongyu Qu Characteristic analysis of adverse reactions of histone deacetylase inhibitors based on WHO-VigiAccess Frontiers in Pharmacology histone deacetylase inhibitor adverse drug reactions chidamide romidepsin vorinostat WHO-VigiAccess |
| title | Characteristic analysis of adverse reactions of histone deacetylase inhibitors based on WHO-VigiAccess |
| title_full | Characteristic analysis of adverse reactions of histone deacetylase inhibitors based on WHO-VigiAccess |
| title_fullStr | Characteristic analysis of adverse reactions of histone deacetylase inhibitors based on WHO-VigiAccess |
| title_full_unstemmed | Characteristic analysis of adverse reactions of histone deacetylase inhibitors based on WHO-VigiAccess |
| title_short | Characteristic analysis of adverse reactions of histone deacetylase inhibitors based on WHO-VigiAccess |
| title_sort | characteristic analysis of adverse reactions of histone deacetylase inhibitors based on who vigiaccess |
| topic | histone deacetylase inhibitor adverse drug reactions chidamide romidepsin vorinostat WHO-VigiAccess |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2025.1563797/full |
| work_keys_str_mv | AT tongnanyin characteristicanalysisofadversereactionsofhistonedeacetylaseinhibitorsbasedonwhovigiaccess AT yuyuliu characteristicanalysisofadversereactionsofhistonedeacetylaseinhibitorsbasedonwhovigiaccess AT chenwenli characteristicanalysisofadversereactionsofhistonedeacetylaseinhibitorsbasedonwhovigiaccess AT xinranfeng characteristicanalysisofadversereactionsofhistonedeacetylaseinhibitorsbasedonwhovigiaccess AT yumenglin characteristicanalysisofadversereactionsofhistonedeacetylaseinhibitorsbasedonwhovigiaccess AT zhongyuqu characteristicanalysisofadversereactionsofhistonedeacetylaseinhibitorsbasedonwhovigiaccess |